MedTrace Logo

Tolerability of a Novel Spectacle Design With Reduced Peripheral Contrast

NCT03761758 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 21

Last updated 2018-12-03

No results posted yet for this study

Summary

Prospective, randomized, subject-masked 3-arm clinical study to assess the pediatric acceptability across three iterations of a novel spectacle lens design.

Conditions

  • Myopia

Interventions

DEVICE

Spectacle lenses

Spectacle lenses with clear central apertures

Sponsors & Collaborators

  • SightGlass Vision, Inc.

    lead INDUSTRY

Principal Investigators

  • Joe Rappon, OD, MS · SightGlass Vision

Study Design

Allocation
RANDOMIZED
Purpose
DEVICE_FEASIBILITY
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
6 Years
Max Age
12 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-05-01
Primary Completion
2018-07-19
Completion
2018-07-19
FDA Device
Yes

Countries

  • Canada

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03761758 on ClinicalTrials.gov